MARTINSRIED, GERMANY and MUNICH, GERMANY and PRINCETON, NJ--(Marketwire - August 11, 2009) -
GPC Biotech AG (FRANKFURT: GPC) (XETRA: GPC) today announced that it will
hold a conference call on Tuesday, August 18, 2009 to discuss its financial
results for the second quarter and first half of 2009. The results will be
published on August 18th in advance of the call.
Participants may listen via live webcast, accessible through the GPC
Biotech Web site at www.gpc-biotech.com, or via telephone. A replay will be
available via the Web site following the live event. The call, which will
be conducted in English, will be held on August 18 at 15:00 CET/9:00 AM ET.
The dial-in numbers for the call are as follows:
Participants in Europe: 0049 (0) 69 667775756
0044 (0)20 3003 2666
Participants in the U.S.: 1-646-843-4608
About GPC Biotech
GPC Biotech AG is a publicly traded biopharmaceutical company focused on
developing anti-cancer drugs. The Company currently has two programs in
clinical development: satraplatin, an oral platinum compound, and
RGB-286638, a multi-targeted protein kinase inhibitor. The Company's
shareholders have approved a merger agreement pursuant to which the Company
will combine its business with Agennix, Incorporated, a privately held
biotechnology company located in Houston, Texas. Agennix is developing
oral talactoferrin, a product candidate that is currently in Phase 3 trials
for non-small cell lung cancer. GPC Biotech AG is headquartered in
Martinsried/Munich (Germany) and has a wholly owned U.S. subsidiary in
Princeton, New Jersey. For additional information, please visit GPC
Biotech's Web site at www.gpc-biotech.com.
This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of GPC Biotech. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause
future results, performance or achievements to differ significantly from
the results, performance or achievements expressed or implied by such
forward-looking statements. Actual results could differ materially
depending on a number of factors, and we caution investors not to place
undue reliance on the forward-looking statements contained in this press
release. Forward-looking statements speak only as of the date on which they
are made and GPC Biotech undertakes no obligation to update these
forward-looking statements, even if new information becomes available in
the future.
